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RESEARCH ARTICLE Open Access
The influence of citrus aurantium and
caffeine complex versus placebo on the
cardiac autonomic response: a double blind
crossover design
Brian Kliszczewicz*† , Emily Bechke†, Cassie Williamson, Paul Bailey, Wade Hoffstetter, John McLester
and Cherilyn McLester
Abstract
Background: The purpose of this study was to examine the resting cardiac autonomic nervous system’s response
to the ingestion of a complex containing Citrus aurantium + Caffeine (CA + C) and its influence on recovery
following a high-intensity anaerobic exercise bout in habitual caffeine users.
Methods: Ten physically active males (25.1 ± 3.9 years; weight 78.71 ± 9.53 kg; height 177.2 ± 4.6 cm; body fat
15.5 ± 3.13%) participated in this study, which consisted of two exhaustive exercise protocols in a randomized
crossover design. On each visit the participants consumed either a CA + C (100 mg of CA and 100 mg of C) or placebo
(dextrose) capsule. After consumption, participants were monitored throughout a 45-min ingestion period, then
completed a repeated Wingate protocol, and were then monitored throughout a 45-min recovery period. Cardiac
autonomic function (Heart Rate (HR) and Heart Rate Variability (HRV)) and plasma epinephrine (E) and norepinephrine
(NE) were taken at four different time points; Ingestion period: baseline (I1), post-ingestion period (I2); Recovery period:
immediately post-exercise (R1), post-recovery period (R2). Heart rate variability was assessed in 5-min increments.
Results: A repeated measures ANOVA revealed significant time-dependent increases in HR, sympathetic related
markers of HRV, and plasma E and NE at I2 only in the CA + C trial (p < 0.05); however, no meaningful changes in
parasympathetic markers of HRV were observed. Participants recovered in a similar time-dependent manner in all
markers of HRV and catecholamines following the PLA and CA + C trials.
Conclusion: The consumption of CA + C results in an increase of sympathetic activity during resting conditions
without influencing parasympathetic activity. CA + C provides no influence over cardiac autonomic recovery.
Keywords: P-synephrine, Heart rate variability, Caffeine, Anaerobic, Recovery
Background
The cultivation of commercially available supplements
has substantially increased throughout recent years,
making the use of pharmacologic ergogenic aids more
prevalent and readily available to the general population
and athletic community. In general, ergogenic aids purport
to contain individually unique properties that result in vari-
ous physiological outcomes (e.g., metabolic); however, a
majority of these claims are overstated or not fully under-
stood. Recently, a growing interest in the combined supple-
mentation of Citrus aurantium (CA) and Caffeine (C) has
emerged due to its ability to decrease rate of fatigue during
exercise and increase metabolic rate [1, 2].
While examining these supplements individually, C has
been known to stimulate the central nervous system
(CNS) (i.e. increase heart rate, cognitive function, blood
pressure) which in turn increases motor function, avail-
ability of plasma free fatty acids, and increased perform-
ance outcomes during endurance exercise [3–5]. Whereas
CA is most popularly used as a weight loss supplement,
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which is attributed to its primary protoalkaloidal constitu-
ent, p-synephrine [6–8]. P-synephrine has an affinity to ß-3
receptors and therefore enhances lipolysis and thermogen-
esis. CA was previously theorized to produce similar effects
on the CNS as ephedra due to p-synephrine’s similarities in
chemical structure. However, it has recently been found
that the influence of CA over CNS appears to be minimal,
although not fully understood [6]. To this point, the litera-
ture is conflicting in regards to the magnitude of the effect
of CA on the cardiovascular system, especially when com-
bined with C [7, 9, 10].
A study conducted by Ratamess et al., [2] supports
the notion that when combined, caffeine (100 mg) and
p-synephrine (100 mg) can increase local muscle endur-
ance within multiple sets during resistance training. The
findings of this study are suggestive of enhanced recovery
between multiple sets [2], which may therefore translate
to the recovery of other mechanisms of physiological
stress and control. The analysis of the autonomic nervous
system (ANS) is a viable method to assess transient alter-
ations and stress on the body, and may also provide
insight into systemic readiness [11]. The homeostatic con-
dition of the body is maintained through the sensitivity
and the responsiveness of the ANS to internal and exter-
nal stimuli [11, 12]. Fluctuations of the ANS are observed
through changes in its two branches; the sympathetic
nervous system (SNS) and parasympathetic nervous
system (PNS). ANS activity can be indirectly measured
through the observation of cardiac autonomic activity
(e.g., vagal and sympathetic modulations), which can be
measured through heart rate variability (HRV). In conjunc-
tion with HRV measures, plasma catecholamines, epineph-
rine (E) and norepinephrine (NE), provide direct markers
of SNS activity and allow for a more holistic view of ANS
function.
To the authors’ knowledge, no known research has been
conducted examining the influence of CA +C complex
supplementation on cardiac autonomic activity and recov-
ery following a high-intensity exhaustive exercise protocol.
Improvements in acute ANS recovery may translate to re-
duce transient stresses within the CV system as well as
prevent systemic over reaching [11, 13, 14]. Therefore, the
purpose of this study was to examine the resting ANS re-
sponse to the ingestion of CA + C as well as its influence




Fourteen apparently healthy males who habitually con-
sume caffeine (95–300 mg serving per day, at least 4 days
a week) were recruited for this study. Prior to participa-
tion, all individuals were made aware of the procedures
and risks associated with the study and signed an
informed consent. A health history questionnaire (HHQ)
and physical activity readiness questionnaire (PAR-Q)
were administered in order to ensure that participants
were capable of engaging in vigorous physical activity
without physician’s clearance as defined by the guidelines
provided by the American College of Sports Medicine
[15]. Any individual who reported having orthopedic con-
ditions, cardiovascular, pulmonary, or metabolic disease
were excluded from the study. Those who regularly over
consumed caffeine (≥ 300 mg/day) were also excluded
from the study.
Physical activity inclusion criteria required all partici-
pants to engage in at least three-days of aerobic training
and two-days of resistance training per week for the pre-
vious six months. Participants were recruited via word of
mouth from the local metropolitan area. Prior to all ses-
sions, participants were asked to wear light and comfortable
clothing, fast for a minimum of four-hours, avoid exercise
for 24 h, and avoid caffeine consumption for 12 h. The
Institutional Review Board approved all testing procedures
and protocols prior to beginning data collection.
Experimental design
The study was performed in a double-blind, placebo-
controlled, randomized crossover fashion in which only
one investigator knew the contents of the supplementa-
tion; this investigator was not involved in the collection
or analysis of the study outcome measures. Participants
were asked to attend two separate sessions in the exer-
cise physiology laboratory, with both visits occurring
within a nine-day period and a minimum of 72-h be-
tween visits. All visits were performed between 5:00 am
7:00 am. The first visit consisted of obtaining informed
consent, PAR-Q, HHQ, and anthropometric measures.
Height (cm) and weight (kg) were collected using an
electronic physicians scale (Tanita WB 3000, Arlington
Heights, IL) and body fat percent (BF%) was collected
via a dual-energy x-ray absorptiometry scan (GE Lunar
iDXA, Madison, WI).
The remaining two visits can be described in two over-
arching sections; the ingestion period with pre and post
time points (I1 & I2) and the recovery period with pre
and post time points (R1 & R2). The ingestion period
consisted of baseline measures (I1), which included vei-
nipuncture and the fitting of a polar heart rate monitor,
followed by the consumption of either the supplement
(CA + C) or placebo (PLA). The 45-min ingestion period
was initiated after the participants consumed CA + C or
PLA. Upon the completion of the ingestion period, a
post-ingestion venipuncture were performed (I2). Partic-
ipants then performed a standardized warm-up prior to
initiating the anaerobic exhaustive exercise protocol. Im-
mediately following the exercise protocol a post exercise
venipuncture was performed (R1). Then, participants
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were monitored throughout a 45-min recovery period.
At the end of this recovery period the final venipuncture
was taken (R2). Cardiac activity was continuously re-
corded during the 45-min ingestion and recovery periods.
Analysis of these recordings were made in 5-min seg-
ments beginning at the 5-10th minutes of the ingestion
and recovery periods. These values are present as time
points I1 & R1 (respectively). Additionally, the 40-45th
minutes of the ingestion and recovery periods and are
present as time points I2 & R2 (respectively). The study
design can be seen in Fig. 1.
Exhaustive exercise protocol
Upon the completion of the 45-min ingestion period,
participants were allotted a seven-and-a-half minute warm
up on a Monark ergometer (Monark 828E Ergomedic Test
Cycle, Vansbro, Sweden) while pedaling between 50 and
100 rpm at a resistance of 1.5 kp. Participants were imme-
diately walked to an electronically braked cycle ergometer
(Sport Excalibur, Lode BV, Groningen, The Netherlands),
where the bike was adjusted to the appropriate settings in
order to ensure the knee was at a slight bend at the bot-
tom of the revolution. Bike settings were repeated for both
trials. Following the appropriate adjustments, participants
feet were strapped into the pedals and the protocol was
initiated. The start of the exhaustive exercise protocol
comprised of a one-minute warm-up period performed
at 50 W with a rolling start into the Wingate test. Each
Wingate test was 30-s in duration and participants were
encouraged to pedal at their maximal effort against a
resistance of 0.80 Nm/kg [16]. There was a total of three
Wingate tests performed with a two-minute active recov-
ery period between each test. The active recovery was a
self-selected pedal rate against a resistance of 50 W and a
rolling start into the subsequent Wingate test. At the
completion of the last Wingate test, participants were
walked to a separate room to undergo a post exercise
venipuncture and to begin the measurements of cardiac
autonomic recovery measures (R1-R2). Pre-testing protocols
on the electronically braked cycle ergometer followed manu-
facturer guidelines.
Blood collection and analysis
A trained phlebotomist drew six milliliters (ml) of blood
via the antecubital vein during four-time periods through-
out the study: I1, I2, R1, R2 (Fig. 1). Blood draws were col-
lected in lithium heparin tubes and inverted based on the
manufactures’ recommendations prior to centrifugation.
Samples were centrifuged at 2500 rpm for 15-min, then
aliquoted and stored in a − 80 °C freezer until subse-
quent assay analysis. Plasma samples were assayed for
E and NE using commercially available ELISA kits (Abnova,
Taoyuan City, Taiwan). In order to account for the plasma
volume shifts following the exercise bout, all samples were
normalized by using the established protocols of Dill and
Costill [17]. Hematocrit (Hct) and hemoglobin (Hb) were
collected via finger sticks at each venipuncture time point
(Alere Hemopoint 2).
Heart rate variability collection and analysis
Heart Rate Variability is a non-invasive measurement
that quantifies the timing between consecutive R-R in-
tervals. The measurements are derived from an electro-
cardiogram or HR detection device (i.e. HR monitors)
[18]. Heart Rate Variability and HR recordings were col-
lected using the Polar® monitor system and transferred
to the Polar Team2 software (Lake Success, NY). Heart
rate monitors were positioned under the sternum against
bare skin. Throughout each 45-min recording period,
participants were seated in a quiet, dimly lit room with
no external stimuli.
Analysis was completed through the online Kubios
Software (Kubios V 2.2, Joensuu, Finland) wherein record-
ings were transformed into a tachogram, which plots the
successive R-R intervals (y-axis) against the number of
beats within the time series (x-axis). Heart Rate Variability
markers were analyzed in five-minute segments during
the beginning (5–10 min: I1, R1) and end (40–45 min: I2,
Fig. 1 Study Design
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R2) of the ingestion and the recovery periods. During ana-
lysis, an artifact correction of “low” with a sensitivity set to
identify any R-R abnormality ±0.35 s was applied using a
piecewise cubic spline interpolation method in order to
filter additional artifact noise present in the tachogram
(Kubios V 2.2, Joensuu, Findland) [19, 20]. Any segments
that contained three or more irregular R-R intervals were
excluded from analysis.
The markers chosen for this study were the time do-
main indexes of the root mean square of successive
differences (RMSSD) and the standard deviation of nor-
mal-to-normal intervals (SDNN); the frequency domain
measures of High Frequency Power (HF) (0.15–0.40 Hz),
normalized High Frequency Power (HFnu), Low Frequency
Power (LF) (0.04–0.15 Hz), normalized Low Frequency
Power (LFnu), and their ratio LF/HF. The Fast Fou-
rier Transformation was applied to the frequency do-
main makers. Frequency domain measures come with
inherent limitations related to ANS interpretation due
to sensitivities to breathing frequencies and therefore will
be assessed along with time domain measures [21]. RMSSD
and HF are widely recognized as markers of vagal activity
[18, 22], while SDNN and LFnu are believed to provide
insight into SNS influence, though they possess activity
from the PNS [23, 24]. LF/HF ratio provides insight into
ANS balance [25]. All R-R interval recordings were mea-
sured using a window width of 256 s and overlap of 50%
through the specialized HRV software (Kubios V 2.2,
Joensuu, Findland).
Supplement preparation
CA and C powder were purchased from Blackburn distri-
butions (Caffeine powder, Blackburn distributions limited,
Nelson Lancashire, England; Citrus aurantium powder,
Blackburn distributions limited, Nelson Lancashire,
England). The PLA contained 200 mg of dextrose, whereas
the supplement contained a combination of CA (100 mg)
and C (100 mg). Each component was measured using an
electronic supplement scale and encapsulated in green,
non-translucent, size zero gelatin capsules. The identity of
the content within the capsules was not revealed until all
data were collected and statistical analyses were completed.
Statistical analysis
All data were analyzed using the statistical software
package SPSS (SPSS, Version 24 for Mac, Chicago, IL).
A Shapiro-Wilk test was performed to examine the
normality of distribution on the HRV markers: RMSSD and
SDNN. In order to assess changes in time within trial (CA
+C/PLA) repeated measures analysis of variance (ANOVA)
were run (Ingestion: I1 vs. I2; Recovery: R1 vs. R2) in cardiac
autonomic markers (HRV and HR) and plasma catechol-
amines (E and NE). Significance for all statistical analyses
was set at ≤0.05. The data is presented as the mean ±
standard deviation (SD). In order to determine the effect
size, the recommended guidelines of Quintana were used.
[26]. Thresholds for effect size were the following; a small
(< 0.25) moderate (0.50), and large effect (0.90).
Results
Four participants were removed from the study due to ad-
verse reactions to the phlebotomy procedure (i.e. vaso-vagal
reactions) (n = 2), pain brought on by brochiospasm (n = 1),
and the presence of more than three irregular R-R intervals
in the recordings (n = 1). Therefore, a total of ten physically
active males completed the study. Participant characteristics
can be seen in Table 1. Additionally, normality was violated
in several HRV markers and therefore the natural logarith-
mic transformation (ln) was applied prior to further statis-
tical analysis: RMSSD (lnRMSSD), SDNN (lnSDNN), HF
(lnHF), LF(lnLF).
During the PLA ingestion phase, no significant (p > 0.05)
time effects were found in any cardiac autonomic markers
or catecholamines except for a significant decrease in HFnu
and a significant increase in LFnu (p < 0.05). However, dur-
ing the CA+C trial ingestion period, a significant time
effect (p < 0.05) was observed from I1 to I2 with increases
in HR, lnSDNN, LFnu, NE, E, and a decrease in HFnu.
While examining the recovery period in the PLA and CA+
C trials, no significant time effects occurred in HFnu, LFnu,
or LF/HF. A significant decrease in HR, lnRMSSD, and
lnSDNN occurred along with a significant decrease in E
and NE. Means ± SD and effect size (Cohen’s d) can be seen
for the ingestion period in Table 2A and the recovery period
in Table 2B.
Discussion
The purpose of this study was to examine the resting ANS
response to the ingestion (I1 - I2) of CA +C as well as its
influence on the ANS response to an exhaustive exercise
protocol (R1 - R2). During the ingestion period HR, lnLF,
LFnu, E and NE significantly increased in the CA +C trial,
indicating an enhanced sympathetic response to the sup-
plementation. Interestingly, a significant decrease in HFnu
was observed while no changes in lnHF or lnRMSSD
occurred despite a significant increase in lnSDNN. All car-
diac autonomic markers demonstrated a time-dependent
shift towards baseline following the exercise protocol
Table 1 Participant Characteristics (N = 10)
Characteristic Mean ± SD
Age (y) 25.1 ± 3.8
Height (cm) 177.2 ± 4.6
Weight (kg) 78.8 ± 9.4
Body Fat (%) 15.5 ± 3.0
Caffeine/day (mg) 209 ± 95.5
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except for LFnu, HFnu, and LF/HF. Further points of con-
sideration are provided below.
Ingestion period
Resting HR is a primary marker in cardiac autonomic
activity and is affected through several intrinsic and ex-
trinsic factors; however, the influence of the combination
of CA + C on resting HR is relatively unknown. The lim-
ited amount of information available pertains to the iso-
lated components CA and C, with only one known study
to have examined the combination of both [2]. For in-
stance, Min et al., [10] examined only p-synephrine, the
active component of CA, and found no changes in resting
HR at one-hour, three-hours, six-hours, or eight-hours
following consumption. Furthermore, recent studies have
shown little no changes in resting HR with caffeine con-
sumption alone in habitual caffeine consumers [27, 28].
When combining a 100 mg of CA, and 100 mg of C, Rata-
mess et al. [2] observed no significant changes in resting
HR following a three-week washout period from caffeine
when compared to controls. In contrast, the findings of
the current study demonstrated a time-dependent in-
crease in HR following the consumption of the CA +C
complex. No time-dependent changes were observed dur-
ing the ingestion phase for the PLA trial. This discrepancy
may be due to differences in the experimental design. For
instance, the participants in the Ratamess et al. [2] study
underwent a three day exposure to the CA +C complex
prior to testing, while in the current study participants were
not given the CA +C complex prior to the experimental
trials, which may account for the difference in the response.
Overall, the evaluation of CA or CA + C on markers
of ANS activity is currently understudied, but informa-
tion regarding other stimulants (e.g. caffeine) is replete
[3–5, 29, 30]. For instance, Rauh et al. [31] found that
the consumption of either 100 mg or 200 mg of caffeine
in habitual users failed to alter any examined marker of
HRV. Zimmerman et al. [28] examined caffeine consump-
tion in both habitual and non-habitual consumers and
found no effect on SNS related activity (LF and LF/HF),
but enhanced PNS activity (RMSSD and HF) in habitual
users was observed. Conversely, Yoshinaga et al., observed
Table 2 Markers of ANS activity during the Ingestion (A) and Recovery Periods (B)
A. Ingestion Period PLA CA + C
I1 I2 p-value Cohen’s d I1 I2 p-value Cohen’s d
Heart Rate (bpm) 62.6 ± 14.34 65.5 ± 10.96 0.60 0.23 59.7 ± 7.93 64.6 ± 9.13 0.04 0.57
lnRMSSD (ms) 3.95 ± 0.49 3.87 ± 0.40 0.57 0.17 4.0 ± 0.50 4.08 ± 0.45 0.45 0.16
lnSDNN (ms) 4.32 ± 4.40 4.40 ± 0.33 0.59 0.22 4.36 ± 0.48 5.04 ± 0.56 0.03 1.28
lnHF (ms2) 6.65 ± 1.00 6.55 ± 0.85 0.70 0.12 6.95 ± 0.79 7.04 ± 0.82 0.70 0.11
HFnu 42.92 ± 16.87 29.37 ± 16.06 0.01 0.82 39.01 ± 17.13 31.78 ± 12.49 0.03 0.48
lnLF (ms2) 7.00 ± 1.00 7.51 ± 0.73 0.21 0.58 7.43 ± 1.05 7.86 ± 0.71 0.05 0.48
LFnu 57.01 ± 16.89 70.62 ± 16.07 0.01 0.82 58.95 ± 20.45 68.20 ± 12.50 0.03 0.55
LF/HF 2.08 ± 2.29 3.20 ± 1.54 0.07 0.57 2.40 ± 2.31 2.75 ± 1.63 0.45 0.18
E (nmol/L) 4.40 ± 2.93 3.97 ± 2.05 0.41 0.17 3.53 ± 2.08 4.96 ± 2.84 0.02 0.58
NE (nmol/L) 21.56 ± 5.57 23.40 ± 9.63 0.51 0.23 18.16 ± 3.91 28.29 ± 7.29 0.00 1.73
B. Recovery Period PLA CA + C
R1 R2 p-value Cohen’s d R1 R2 p-value Cohen’s d
Heart Rate (bpm) 102.56 ± 10.79 87.6 ± 11.30 0.00 1.35 111.56 ± 11.37 94.4 ± 9.77 0.00 1.35
lnRMSSD (ms) 1.42 ± 0.49 2.54 ± 0.66 0.00 1.90 1.51 ± 0.84 2.50 ± 0.68 0.03 1.29
lnSDNN (ms) 2.90 ± 0.31 3.57 ± 0.49 0.01 1.62 2.89 ± 0.45 3.71 ± 0.58 0.01 1.59
lnHF (ms2) 1.59 ± 0.62 3.92 ± 1.30 0.00 2.30 1.50 ± 1.50 4.23 ± 1.22 0.00 2.01
HFnu 12.33 ± 7.30 13.61 ± 11.11 0.78 0.14 19.37 ± 20.31 18.00 ± 13.06 0.71 0.08
lnLF (ms2) 3.69 ± 0.97 6.04 ± 1.26 0.00 2.09 3.19 ± 1.12 5.71 ± 1.50 0.00 1.90
LFnu 87.62 ± 7.27 86.37 ± 11.14 0.78 0.13 80.45 ± 20.50 81.95 ± 13.11 0.69 0.09
LF/HF 9.69 ± 4.83 12.18 ± 12.00 0.47 0.27 7. 63 ± 4.22 7.18 ± 5.15 0.82 0.09
E (nmol/L) 31.50 ± 19.09 4.22 ± 2.91 0.00 2.00 38.24 ± 26.44 5.50 ± 2.34 0.00 1.74
NE (nmol/L) 158.20 ± 82.26 30.11 ± 14.08 0.00 2.17 179.14 ± 61.37 35.20 ± 8.51 0.00 3.2
Chronotropic markers of ANS activity is represented as HR; Markers of Heart Rate Variability (HRV) are the log transformed mean square of successive N-N intervals
(lnRMSSD), standard deviation of the N-N intervals (lnSDNN), the High Frequency (lnHF), Low Frequency (lnLF) and the ratio (LF/HF); Plasma Catecholamines are
represented as Epinephrine (E) and Norepinephrine (NE). All data are presented as Means ± SD
≤ 0.05 significant time effects
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significant increases in the power spectral density in both
LF and HF following the ingestion of 4 mg•kg of body-
weight [32]. The findings of the current study provide
equivocal results to the literature, where the consumption
of CA +C increased HR, lnLF, LFnu, E, and NE; indicating
an increase in SNS activity while showing no changes in
PNS markers (lnRMSSD and lnHF) during the ingestion
period. Interestingly, a nonsignificant rise of lnLF and re-
duction of lnHF was observed following the PLA trial.
However, when evaluating LFnu and HFnu a similar yet
significant changed was observed, demonstrating a relative
change in the ratios rather than the absolute values of the
power spectral density. This may in part be due to the
anticipation of the upcoming exhaustive protocol and
pre-performance anxiety, resulting in minor shifts of ANS
activity. Future studies should evaluate and account for
pre trial emotional stress.
When evaluating plasma markers of SNS activity, it
has been proposed that circulating sympathetic bio-
markers E and NE increase following consumption of
caffeine [33, 34]; however, a recent study demonstrated
caffeine to have little to no influence over resting values
[35]. The observed changes in E and NE within the
current study support the previous notion that caffeine
influences resting plasma levels and reflect the changes
observed in SNS related HRV markers following the CA
+ C ingestion. The lack of change in the lnRMSSD and
lnHF in the presence of increased SNS activity acts
against the traditional interplay between PNS and SNS
balance. Generally, with increases in SNS activity a with-
drawal of vagal tone occurs. However, this was not ob-
served and could be the result of a decreased sensitivity
to caffeine or the rested state of the participant, which
resulted in the attenuation of vagal activity.
Regardless of the mechanisms involved, the overall
cardiac autonomic response observed during the inges-
tion phase is suggestive of a “priming” of the SNS re-
sponse to the CA + C supplementation. Traditionally, it
is believed that ANS activity is balanced between the
PNS and SNS branches, exhibiting an inverse relation-
ship [12]. However, the PNS/SNS interplay appears to be
more complex, and likely exhibits their influences upon
each other on a spectrum, rather than direct counter
balance. The findings of this study are indicative of this
type of relationship between the SNS and PNS branches,
specifically the lack of change in resting PNS activity
when compared to the time-based increases in SNS
drive observed in the CA + C trial. Specifically, there was
an increase in lnSDNN and lnLF without the presence
of altered vagal activity. This is important because these
markers are believed to have influences stemming from
both the SNS and PNS [36]. Therefore, with no discern-
able changes within markers of vagal activity, it can be
inferred that the increases of lnLF and lnSDNN are the
result of changes seen in SNS activity. This response
adds to the understanding of the level of complexity
within ANS control and should be further investigated
to determine thresholds between the various markers.
Recovery period
Following the exhaustive protocols, HR was signifi-
cantly elevated in both trials and recovered in a similar
time-dependent fashion (Table 2A and B). This is con-
sistent with the findings of Haller et al. [37] who did
not observe any differences in post-exercise recovery of
HR when comparing a commercially available supplement
(21 mg of synephrine, 303.8 mg of caffeine, and various
additives) to a placebo during the 30-min to 12-h follow-
ing a moderate exercise bout [37]. Additionally, markers
of HRV following the exhaustive protocol demonstrated
nearly identical physiological responses, with a decrease in
activity post exercise and a gradual increase toward base-
line values, which is a commonly observed post exercise
response [11, 38]. A similar yet inverse response was
observed in circulating plasma E and NE, with substantial
increases post exercise and a return to baseline values
within 45-min post (R2). It is important to note that
though increased SNS activity was observed following the
ingestion of CA +C, the effect was lost following the ex-
haustive protocol. Therefore, the findings are suggestive
that the influence of CA +C occurs only in a resting envir-
onment and does not influence the recovery of the system.
Though it was outside the scope of the current study
to establish mechanisms involved with CA + C con-
sumption, we will postulate on potential factors involved
in the observed findings. The ingestion phase (I1 - I2) at
rest was the only period in which CA + C appeared to
have an effect on SNS activity. As previously mentioned,
recent studies have demonstrated that C provides little
cardiovascular stimulation and more so acts to improve
PNS activity rather than inhibit in habitual users [28].
However, it should not be overlooked that the research
is conflicting in habitual consumers and that C has been
shown to alter SNS activity through increased sensitivity to
circulating E and NE [29]. Within the current study, plasma
E and NE significantly increased following CA +C inges-
tion in our habitual C population (209 ± 95.5 mg/day).
There was no withdrawal of PNS activity despite a signifi-
cant increase in resting HR, which could be explained by
the combined effects of circulating E and NE as well as
improved sensitivity related to C. The acting ingredient of
CA, p-synephrine, works primarily on the ß-3 receptors on
adipose tissue and therefore is unlikely to have any dir-
ect impact on autonomic function [7]. Indirectly, the
increased activity of lipolysis, and thermogenesis caused
by p-synephrine could have elevated SNS activity, which
was demonstrated by Reimann et al. [39] who found that
acute hyperlipidemia increased both HR and sympathetic
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drive. Though we did not measure changes in plasma lipids
we can postulate that the known action of p-synephrine
could have elevated plasma levels and consequently influ-
enced sympathetic activity.
Conclusion
In summary, the CA + C complex (100 mg each) used in
this study was enough to elicit what can best be de-
scribed as a priming of the SNS response after consump-
tion. As such, the physiological aspects involved with
CA + C supplementation appear to have the greatest in-
fluence in a resting environment. Beyond modest in-
creases in SNS activity at rest, little benefit was observed
during the exhaustive protocol recovery period, which
was the primary purpose of the investigation. Therefore,
the authors conclude that in healthy male participants
who regularly consume caffeine, CA + C does not im-
prove recovery of cardiac autonomic function following
an exhaustive exercise protocol. The observed priming
of the SNS activity with no alterations of PNS activity
provided new insight into the complex relationship of
the ANS and warrants further investigation.
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